51. Scleroderma Clinical trials / Disease details


Clinical trials : 523 Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02801305
(ClinicalTrials.gov)
June 20169/6/2016Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital UlcersAssessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers.Digital Ulcer of SclerodermaDrug: Diltiazem Gel 2%;Drug: Nitroglycerin Ointment 2%;Drug: VaselineMohammad Ali NazariniaShiraz University of Medical SciencesCompleted20 Years70 YearsAll90Phase 2Iran, Islamic Republic of
2NCT00577304
(ClinicalTrials.gov)
December 200718/12/2007A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's PhenomenonA Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's PhenomenonRaynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Other Autoimmune DiseaseDrug: Nitroglycerin;Drug: Topical AmphiMatrixMediQuest TherapeuticsNULLActive, not recruiting15 Years70 YearsBoth200Phase 3United States
3NCT00419419
(ClinicalTrials.gov)
December 20064/1/2007Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's PhenomenonPhase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's PhenomenonRaynaud's Disease;Scleroderma;Autoimmune DiseasesDrug: Topical AmphiMatrix with nitroglycerin (MQX-503)MediQuest TherapeuticsNULLCompleted18 Years70 YearsBoth80Phase 3United States;Sweden;United Kingdom
4EUCTR2005-004979-37-GB
(EUCTR)
27/11/200618/09/2006 Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as sclerodermaProduct Name: MQX-503
Product Code: MQX-503
INN or Proposed INN: 10% Nitroglycerine in Propylene Glycol, USP
Other descriptive name: Nitroglycerine gel
MediQuest Therapeutics, Inc.NULLNot Recruiting Female: yes
Male: yes
100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom;Sweden
5EUCTR2005-004979-37-SE
(EUCTR)
27/10/200608/09/2006Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2 Moderate to severe primary Raynaud’s,OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as sclerodermaProduct Name: MQX-503
Product Code: MQX-503
INN or Proposed INN: 10% Nitroglycerine in Propylene Glycol, USP
Other descriptive name: Nitroglycerine gel
MediQuest Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
100Phase 3United Kingdom;Sweden
6NCT00378521
(ClinicalTrials.gov)
July 200618/9/2006Dose Response Study of a Topical Gel for the Treatment of Raynaud's PhenomenonPhase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's PhenomenonRaynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Autoimmune DiseaseDrug: MQX-503MediQuest TherapeuticsNULLCompleted18 Years75 YearsBoth15Phase 2United States
7NCT00253331
(ClinicalTrials.gov)
November 200413/11/2005Lab Study of MQX-503 in Treatment of Raynaud'sPhase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s PhenomenonRaynaud Disease;Raynaud Disease Secondary to Scleroderma;Raynaud Secondary to Other Autoimmune DiseaseDrug: topical organogel with nitroglycerinMediQuest TherapeuticsNULLCompleted18 Years80 YearsBoth36Phase 2/Phase 3United States